Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.391 - Pharmacist-led Risk-based β-Lactam Challenges in Patients with Penicillin Allergy: Impact on Antibiotic Days
D1.381 - Antibiotic Allergy De-labelling in Children: Outcomes of Drug Provocation Testing and Feasibility of Non-Specialist Pathways to de-labelling
D1.382 - Vitamin K–Induced Anaphylaxis: A Case Series from a Tertiary Hospital in Manila, Philippines (2024–2025)
D1.384 - Safe Sulfonamide Delabeling in HIV-Negative Adults: Real-World Evidence with TMP-SMX Oral Challenge and SULF-FAST
D1.385 - Lamotrigine-induced Stevens-Johnson syndrome in a pediatric patient with Takayasu arteritis: the steroid paradox
D1.387 - Long-term Follow-up Outcomes of Patients Undergoing Desensitization for Non-Immediate Hypersensitivity Reactions Associated with Lenalidomide
D1.388 - Aspirin maintenance after boost with dupilumab in aspirin-exacerbated respiratory disease
D1.390 - Hypersensitivity Reactions to Biological Agents in a Tertiary Hospital: A 3.5-Year Retrospective Study
D1.392 - Drug-Induced Hypersensitivity Syndrome Associated with β-Lactams and Hemophagocytic Lymphohistiocytosis: Overlapping Disorders or a Causal Relationship?
D1.393 - Safety of Aspirin Oral Provocation in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
D2.441 - Association of High Sensitive-C-reactive Protein with Left Ventricle Remodeling in Type 1 Diabetes Mellitus
D2.443 - Serum Zonulin Reflects Disease Activity and Psychiatric Burden in Hereditary Angioedema
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management
Download the app
The congress at your fingertips
Available on
Download